Vext Announces Q2 2025 Financial Results: Record Quarterly Revenue with Strong 31% Cash Flow Margin

Core Insights - Vext Science, Inc. reported record financial results for Q2 2025, with revenue reaching $13.4 million, a 59% increase year-over-year, and a strong cash flow margin of 31% [4][7][3] Financial Performance - Revenue for Q2 2025 was $13,407,000, compared to $11,561,000 in Q1 2025 and $8,427,000 in Q2 2024 [3] - Adjusted EBITDA for Q2 2025 was $4,077,000, up from $3,357,000 in Q1 2025 and $1,084,000 in Q2 2024, reflecting a significant year-over-year increase [3][13] - Operating cash flow for Q2 2025 was $4,175,000, compared to $(592,000) in Q2 2024 and $3,082,000 in Q1 2025, indicating improved operational efficiency [3][11] Market Dynamics - The growth in revenue and adjusted EBITDA was driven by strong performance in Ohio, where retail sales increased by 86% sequentially [4][7] - Vext is on track to reach the state dispensary license cap of eight by early 2026, enhancing its market presence in Ohio [7][22] Operational Highlights - The company maintained profitability in Arizona despite market contraction by focusing on sell-through on its own retail shelves [4] - Vext's disciplined operations and scalable footprint contributed to its strong cash flow generation and overall financial health [4][7] Recent Developments - Vext completed the acquisition of two cannabis dispensaries in Ohio, which contributed to the revenue growth in Q2 2025 [12] - The company has plans to open additional dispensaries, including a new location in Fairfield, Ohio, expected to begin operations in Q4 2025 [12][22]